Akonni signs license agreement with USAMRIID to develop multiplex testing items for bio-security applications Akonni Biosystems, a molecular diagnostics business that develops rapid, low-price and highly scalable solutions for infectious disease assessment, announced it provides signed a license contract with the U today.S. Army Medical Study Institute of Infectious Diseases . Having gain access to to this content will allow Akonni Biosystems to more rapidly commercialize a family group of highly multiplexed assessments for analysis and in vitro diagnostics uses in global bio-security applications. Financial conditions were not disclosed. Related StoriesNew medical chemistry analyzer released by EKF at Medica 2015Point-of-care diagnostics for EbolaNew study from TSRI and Salk factors to cause of debilitating nerve disease We are excited to partner with USAMRIID on creating a series of low-cost, multiplex testing products to protect our war-fighters, first responders and citizens from some of the most dangerous bio-threat agents that you can buy, says Akonni’s CEO, Dr.After artificial or spontaneous membrane rupture, a Goldtrace fetal scalp electrode was put into each woman who consented to participate in the trial. If it was not possible to acquire or maintain a satisfactory fetal ECG signal after three tries at electrode placement or if an ST-segment event occurred during the efforts to obtain an adequate signal, the girl was excluded from randomization. The masked S31 monitors functioned as conventional electronic fetal heart-rate monitors. The care of individuals in the masked group was managed at the discretion of the attending doctor or midwife. S31 monitors in the open setting displayed ECG ST-segment details intended for use when uncertain fetal heart-rate patterns were detected.